On the morning of July 13, the 2023 International Conference on Pharmaceutical Innovation and Development started in Yantai Bajiaowan International Convention and Exhibition Center, hosted by People’s Government of Shandong Province, co-organized by Chinese Pharmaceutical Association, China Pharmaceutical Innovation and Research Development Association, China Society for Drug Regulation and Shandong Administration for Market Regulation, and organized by the People’s Government of Yantai and Shandong Drug Administration. Jiao Hong, Director of the National Medical Products Administration; Wang Guiying, Vice Governor of Shandong Province; Zhao Xiangeng, an academician of the Chinese Academy of Engineering; Pei Gang, an academician of the Chinese Academy of Sciences; Zhang Wei, President of the China Society for Drug Regulation; Jin Shenghao, Director of Medicity Daegu; and Zheng Deyan, Deputy Secretary of the Yantai Municipal Committee of the CPC and Mayor of Yantai, attended the conference and delivered speeches.
The theme of the conference is “Innovation is the Driving Force to Lead High-quality Development”. The conference included theme promotion, promotion of Yantai biomedical industry achievements and park carrier, and promotion of Yantai biomedical health industry development fund of funds; launch of the first batch of sub-fund projects and innovation institutions of Yantai biomedical health industry development fund of funds; and keynote speeches, academician forums and concentrated signing of key projects.
In the session of launching innovation institutions, “Yantai Institute of Life Sciences and Medicine” and “Yantai Technology Innovation Institute for Stem Cell and Regenerative Medicine”, jointly established by BMU, local governments and pharmaceutical companies, were unveiled. In the presence of the participating experts, scholars and leaders, Zhao Shengtian, President of BMU, jointly unveiled “Yantai Institute of Life Sciences and Medicine” and “Yantai Technology Innovation Institute for Stem Cell and Regenerative Medicine” with Sun Xianze, President of the Chinese Pharmaceutical Association; Xi Yan, Counselor of People’s Government of Shandong Province and President of Shandong Provincial Medical Association; Wu Chengbing, Secretary of the Party Leadership Group and Director of the Shandong Administration for Market Regulation; Cheng Maosheng, President of Shenyang Pharmaceutical University; Hu Baoyang, Executive Director of Beijing Institute of Stem Cell and Regenerative Medicine; Li Jian, Deputy Secretary of the Muping District Party Committee and Chief Executive of Muping District; and Sha Junming, General Manager of Yantai Biomedical Health Industry Development Group Co., Ltd.
According to the introduction, Yantai Institute of Life Sciences and Medicine was approved in December 2022 as a research institute jointly established by BMU and Yantai Market Supervision Administration, People's Government of Muping District, Yantai Biomedicine and Health Industry Development Group Co. and Guoyuan Life Science Group Co., Ltd.
As the management institution of the “Demonstration Base of Technology Transfer of National Key Research and Development Program Project”, the institute relied on the talent resources from University's characteristic specialties and predominant disciplines, brought together high-level and specialized scientific research and innovation teams, integrated various research centers (institutes) and public scientific research platforms, pushed forward the transformation of relevant scientific research achievements, and provided talent resources and good conditions for the development of scientific and technological innovations in the field of biomedicine.
According to the agreement to jointly build the institute, the University and Yantai Biomedical Health Industry Development Group Co., Ltd jointly established the Yantai Stem Cell and Regenerative Medicine Innovation Institute managed by the University. The institute mainly focuses on cultivating talents of cells, genes, regenerative medicine and other majors and conducting joint scientific research projects, providing the Yantai Institute of Life Sciences and Medicine with talents and resources.
The co-establishment of “Yantai Institute of Life Sciences and Medicine” and “Yantai Technology Innovation Institute for Stem Cell and Regenerative Medicine” is an important initiative of the University to deepen the combination between school and locality, which can provide great support of talents and innovation for the development of the biomedical industry in Yantai and the creation of the Innovative high quality Medicine Made in Yantai industrial brand, and inject new momentum into the high-quality development of Yantai's biomedical industry.
BY: Chen Xikun
SOURCE: News Center